The Swiss pharma giant intends to nearly double its operational footprint in the state to more than 700,000 square feet between the existing campus and new facilities.
The clinical-stage biotech company will leverage AGC’s BravoAAV suspension platform for two novel candidates to address progressive and irreversible vision loss.
Expansion at the facility will roll out in phases and position the South Korea–based biosimilars manufacturer to build an integrated U.S. manufacturing supply chain.
Faced with increasing quality, risk, and talent pressures, pharma manufacturers are embracing smart manufacturing and automation to overcome these challenges. Find out in this...
Advancements in cleanroom technology are redefining pharmaceutical manufacturing with energy-efficient HVAC, sustainable materials, and intelligent airflow. However, much more...
Explore proven alternatives to fetal bovine serum (FBS). Discover how donor bovine serum and other options can reduce cost and supply risks while maintaining performance in bioproductio...
Join industry specialists as they share their insights, experiences, and strategies to enhance efficiency, reduce costs, and improve product quality in the production of non-traditional...
This week, the industry saw a flurry of pharma manufacturing investment announcements as companies continue to onshore production in the United States.
Eli Lilly and Novo Nordisk are latest to accept quid pro quo of Most Favored Nation drug pricing and onshoring of pharmaceutical manufacturing for tariff exemptions.
While Big Pharma has the resources to invest in domestic production, smaller biotech companies increasingly rely on contract manufacturers who need help.
Raleigh-Cary and Durham-Chapel Hill secured the first and third spots, respectively, as the nation’s most competitive markets for the production of therapeutic biologics.
SymphonX, which runs all downstream unit operations in both fed-batch and continuous processes, will serve customers at Fujifilm’s Billingham manufacturing facility.
With $1.3 billion in funding, the company has established a cGMP manufacturing facility in Waltham, Massachusetts, with a second site under construction in Pittsburgh.
Panelists at the 2025 Cell & Gene Meeting on the Mesa laid out the challenges and opportunities facing the industry as it looks to produce these therapies at scale.
The agency is reviewing clinical trials that involve sending U.S. patients’ living cells to China and other “hostile countries” for genetic engineering and return infusion.
With manufacturers under increasing pressure to reduce costs, enhance compliance, and accelerate production timelines for high quality drugs, they are increasing their investments...
Improve bioreactor performance, accelerate process development from benchtop to production, assess respiratory efficiency with continuous CO2 monitoring, eliminate potential interferenc...
Software platforms can seamlessly integrate with emerging technologies to unlock efficiencies, strengthen sustainability and enable proactive prevention of disruptions.
Pharmaceutical manufacturing operates in a high-stakes environment where regulatory compliance, product integrity, and operational uptime are non-negotiable. As the industry becomes...
Discover the latest contract manufacturing key trends for the life science industry, including compliance, digital transformation and more. Don't let your organization fall behind...
As the life sciences sector evolves with personalized medicine, biologics, and digitalization, manufacturers must innovate, invest in advanced tech, and adopt agile manufacturing...
Marc Casper contends Thermo Fisher’s pharma and biotech customers will be able to navigate the Trump administration’s MFN drug pricing framework and tariffs.
This episode of Off Script: A Pharma Manufacturing Podcast features a conversation with Jana Falkenberg, senior legal counsel and corporate compliance officer at Vetter Pharma...
CEO Pascal Soriot announced the deal with President Trump on Friday, noting that it includes a three-year exemption from U.S. tariffs for AstraZeneca’s products.
Designed for the review of abbreviated new drug applications, the program is meant to strengthen the domestic pharmaceutical supply chain in the United States.
Cytiva’s 2025 Global Biopharma Index shows widening gaps across regions as talent shortages, regulatory strain, and uneven sustainability progress weigh on growth.
The industry’s inability to make products efficiently and at scale is due to the complexity of the supply chain, panelists said at the Cell & Gene Meeting on the Mesa.
Read more about how WarmMark QR addresses today’s common cold chain monitoring challenges through an innovative combination of visual and digital tracking.